Company: MDCXW
Filing Date: 2025-06-23
Form Type: CORRESP
Source: 0001062993-25-012069
Chunk: 1

Company: Medicus Pharma Ltd.
Filing Date: 2025-06-23
Form: CORRESP
Chunk 1
---
 the intended goals of a consolidation or share split and why such actions would be necessary or desirable in furtherance of the Company's business objectives or capital raising activities.

Response: Please see the Company's response to Comment 1 above. The Company advises the Staff that as a result of the removal of Proposal 5 in the Proxy Statement the disclosure discussed in this Comment does not appear in Amendment No. 1.

3.Please revise your disclosure to include relevant risks associated with a potential share consolidation. Such risks may include that a consolidation may decrease the liquidity of your common stock, may not increase the price of your common stock in the long term, and that it may cause you to fall out of compliance with the Nasdaq Continued Listing Standards, if true.

Response: Please see the Company's response to Comment 1 above. The Company advises the Staff that as a result of the removal of Proposal 5 in the Proxy Statement the disclosure discussed in this Comment does not appear in Amendment No. 1.

June 23 2025
Page 3

We appreciate the Staff's assistance in reviewing this response letter and the Proxy Statement. Please direct any questions that you have with respect to the foregoing or if any additional supplemental information is required by the Staff, to the undersigned at (212) 373-3434.

| Very truly yours,           |
| /s/ Christopher J. Cummings |
| Christopher J. Cummings     |

cc:Laura Crotty

Joshua Gorsky

Securities and Exchange Commission

Raza Bokhari, MD

Medicus Pharma Ltd.

Aaron Sonshine

Bennett Jones LLP